[go: up one dir, main page]

ATE311476T1 - Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) - Google Patents

Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)

Info

Publication number
ATE311476T1
ATE311476T1 AT01306983T AT01306983T ATE311476T1 AT E311476 T1 ATE311476 T1 AT E311476T1 AT 01306983 T AT01306983 T AT 01306983T AT 01306983 T AT01306983 T AT 01306983T AT E311476 T1 ATE311476 T1 AT E311476T1
Authority
AT
Austria
Prior art keywords
gene
polymorphisms
oatp
organic anion
oatpc
Prior art date
Application number
AT01306983T
Other languages
English (en)
Inventor
Monisola Adeokun
Helen Jean Ambrose
Carl John Cresswell
Adam Jeston Dudley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE311476T1 publication Critical patent/ATE311476T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6825Nucleic acid detection involving sensors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01306983T 2000-08-23 2001-08-17 Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) ATE311476T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22690900P 2000-08-23 2000-08-23

Publications (1)

Publication Number Publication Date
ATE311476T1 true ATE311476T1 (de) 2005-12-15

Family

ID=22850936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01306983T ATE311476T1 (de) 2000-08-23 2001-08-17 Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)

Country Status (8)

Country Link
US (2) US20020090622A1 (de)
EP (2) EP1589115A3 (de)
JP (1) JP2002330758A (de)
AT (1) ATE311476T1 (de)
CY (1) CY1106070T1 (de)
DE (1) DE60115349T2 (de)
DK (1) DK1186672T3 (de)
ES (1) ES2252159T3 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223217A4 (de) 1999-09-21 2003-06-25 Chugai Pharmaceutical Co Ltd Transporter-gene oatp-b, c, d und e
GB0213580D0 (en) * 2002-06-13 2002-07-24 Astrazeneca Ab Methods
GB0317592D0 (en) * 2003-07-26 2003-08-27 Astrazeneca Ab Method
EP1784504A2 (de) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) C463a-polymorphismus des oatp-c-gens als grundlage für das variable ansprechen auf die statintherapie
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
JP2011512813A (ja) 2008-02-29 2011-04-28 アイシス イノベーション リミテッド 診断法
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
EP2267153A1 (de) 2009-05-26 2010-12-29 Université Claude Bernard Lyon 1 Identifizierung der Netrin-1-Rezeptor-unc5c-Genmutation bei festen Krebsen
AU2012322018B2 (en) 2011-10-13 2017-09-21 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
JP7067896B2 (ja) * 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO2000008157A2 (en) * 1998-08-07 2000-02-17 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov

Also Published As

Publication number Publication date
US20040235006A1 (en) 2004-11-25
EP1186672A2 (de) 2002-03-13
DK1186672T3 (da) 2006-03-06
ES2252159T3 (es) 2006-05-16
EP1186672A3 (de) 2002-09-25
DE60115349D1 (de) 2006-01-05
CY1106070T1 (el) 2011-06-08
EP1186672B1 (de) 2005-11-30
DE60115349T2 (de) 2006-08-10
US20020090622A1 (en) 2002-07-11
EP1589115A2 (de) 2005-10-26
EP1589115A3 (de) 2006-05-31
JP2002330758A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
IL153052A0 (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
NO20063624L (no) FC region varianter
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
DE60235005D1 (de) Nachweis der instabilität von mikrosatelliten und
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
NO20055741D0 (no) Nye kjemiske forbindelser
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
EP1469084A3 (de) Polymorphismen im menschlichen KDR Gene
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
NO20053903D0 (no) Nukleotidlipidesterderivater.
EP1472375A4 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
ATE528392T1 (de) Neues protein und dessen dns
EP1184465A3 (de) Verfahren zur Diagnose von Polymorphismen des humanen MCT-1 Gens sowie hierdurch definierte Wirkstoffe
WO2002068687A8 (en) Function and application of tob gene in central nervous system of mammal
DE60222669D1 (de) Asthma-assoziiertes gen
WO2002072888A3 (en) Polymorphisms in the human cmoat gene and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1186672

Country of ref document: EP